PE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
- Recombinant
- RabMAb
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Recombinant Monoclonal MIP-1 alpha/CCL3 antibody - conjugated to PE. Suitable for Flow Cyt (Intra), ICC/IF and reacts with Human, Mouse samples.
View Alternative Names
G0S19-1, MIP1A, SCYA3, CCL3, C-C motif chemokine 3, G0/G1 switch regulatory protein 19-1, Macrophage inflammatory protein 1-alpha, PAT 464.1, SIS-beta, Small-inducible cytokine A3, Tonsillar lymphocyte LD78 alpha protein, MIP-1-alpha
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - PE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB317071)
Flow cytometry staining of Human PBMCs (top) or PBMCs treated with 1μg/ml LPS and 1μg/ml Brefeldin A for 18h (bottom), with ab317071 (right) or Rabbit IgG (monoclonal) Phycoerythrin Isotype Control (ab209478) (left). Cells were fixed and permeabilised with BD Cytofix/Cytoperm™ for 20 min. Cells were incubated for 30 min on ice in 1x PBS containing 10μg/ml human IgG and 10% normal goat serum to block FC receptors and non-specific protein-protein interaction followed by the antibody ab317071 or Rabbit IgG (monoclonal) Phycoerythrin Isotype Control (ab209478) (1x 106 in 100 μl at 0.04 μg/ml (1/12500)) for 30min on ice. The cells were simultaneously stained with CD14.
Acquisition of >30000 events were collected using a 50mW Yellow/Green laser (561nm) and 585/16 bandpass filter. Events were gated on viable cells.
Related conjugates and formulations (4)
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
-
Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
-
Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The MIP-1 alpha functions as a chemotactic cytokine. It binds to receptors like CCR1 and CCR5 on the surface of target cells resulting in activation and migration toward areas of inflammation. MIP-1 alpha does not form a complex with other proteins; however its interactions with its receptors are vital for signal transduction. It also promotes the production of additional inflammatory cytokines contributing to amplifying immune responses. The chemotactic properties of MIP-1 alpha make it an important player in the body's defense against pathogens.
Pathways
MIP-1 alpha is involved in important immune pathways like the NF-kB signaling pathway. This pathway plays a significant role in immune cell activation and the inflammatory response. MIP-1 alpha interacts with other chemokines like CCL4 (MIP-1 beta) which shares similar functions and binds to CCR5. The coordinated activities of these chemokines enhance the recruitment and activation of various leukocyte populations facilitating an effective immune response.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com